Aromatic adducts and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Spanish cohort.
In this case-cohort study, we examined the association between bulky DNA adducts and the risk of lung cancer within the European Prospective Investigation into Cancer and Nutrition (EPIC) Spanish cohort with an average 7-year follow-up, including 98 cases of primary lung cancer and 296 subjects randomly selected from the cohort. Aromatic adducts were measured using (32)P-postlabeling in leukocyte DNA from blood samples collected at enrollment. The association between DNA adducts and the risk of lung cancer was estimated using a Cox proportional hazards model with a modified partial likelihood. There was an overall significant increased risk for developing lung cancer when DNA adduct concentrations were doubled, with relative risk (RR) adjusting for all relevant confounders of 1.36 with 95% confidence interval (CI) 1.18-157. There was a significant increased risk for developing lung cancer when DNA adduct concentrations were doubled for current smokers and among subjects exposed to PAH at work; there was also a slightly higher increase among males than females. However, no statistically significant differences were observed for the effect of adduct levels across smoking status, sex or occupational exposure to PAH. A meta-analysis combined four prospective studies, including this study, resulting in a significant association among current smokers, with an overall estimate of 34% increase in the risk of lung cancer when doubling the level of aromatic DNA adducts in leukocytes.
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Tamra
T
Gilberson
Cancer Risk Factor Branch, ISPO-Cancer Prevention and Research Institute, Florence 50131, Italy.
Marco E M
ME
Peluso
Cancer Risk Factor Branch, ISPO-Cancer Prevention and Research Institute, Florence 50131, Italy.
Armelle
A
Munia
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Leila
L
Luján-Barroso
Granada Cancer Registry, Andalusian School of Public Health, Granada 18080, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
María-José
MJ
Sánchez
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Department of Epidemiology, Murcia Health Council, Murcia 30003, Spain.
Carmen
C
Navarro
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Public Health Division of Gipuzkoa, BIODonostia Research Institute, Department of Health of the regional Government of the Basque Country, San Sebastian 48902, Spain.
Pilar
P
Amiano
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Public Health Institute of Navarra, Pamplona 31003, Spain.
Aurelio
A
Barricarte
Public Health Directorate, Asturias 31003, Spain.
J Ramón
JR
Quirós
Granada Cancer Registry, Andalusian School of Public Health, Granada 18080, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Esther
E
Molina-Montes
Granada Cancer Registry, Andalusian School of Public Health, Granada 18080, Spain, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Emilio
E
Sánchez-Cantalejo
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Department of Epidemiology, Murcia Health Council, Murcia 30003, Spain.
María-José
MJ
Tormo
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Department of Epidemiology, Murcia Health Council, Murcia 30003, Spain.
María-Dolores
MD
Chirlaque
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Public Health Institute of Navarra, Pamplona 31003, Spain.
Eva
E
Ardanaz
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Public Health Division of Gipuzkoa, BIODonostia Research Institute, Department of Health of the regional Government of the Basque Country, San Sebastian 48902, Spain.
Miren
M
Dorronsoro
Unit of Analytical Citology and Bimolecular, ISPO-Cancer Prevention and Research Institute, Florence 50131, Italy and.
Massimo
M
Confortini
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Catalina
C
Bonet
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain, Molecular Epidemiology Group, Translational Research Laboratory, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Núria
N
Sala
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Carlos A
CA
González
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain, a.agudo@iconcologia.net.
Antonio
A
Agudo
D000230:Adenocarcinoma / Q000235:genetics*; D016022:Case-Control Studies; D018736:DNA Adducts / Q000235:genetics*; D006801:Humans; D007962:Leukocytes / Q000378:metabolism; D008175:Lung Neoplasms / Q000235:genetics*; D016016:Proportional Hazards Models; D012307:Risk Factors; D013030:Spain
D018736:DNA Adducts